{Reference Type}: Journal Article
{Title}: New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.
{Author}: Simon N;Atiq S;Sonpavde G;Apolo A;
{Journal}: Urol Clin North Am
{Volume}: 51
{Issue}: 3
{Year}: 2024 Aug
{Factor}: 2.766
{DOI}: 10.1016/j.ucl.2024.03.005
{Abstract}: Penile cancer is a rare malignancy with a poor prognosis. Studies with single-agent immune checkpoint inhibitors (ICIs) have demonstrated efficacy, but response rates are low. Studies combining ICIs with both chemotherapy and targeted therapy are ongoing. Up to 50% of penile cancer cases are associated with human papillomavirus (HPV). HPV-targeting therapies, such as HPV-targeting vaccines and T-cell receptor therapies, are an area of active investigation. Penile cancer cells also express cell surface antigens that may be targeted by the emerging class of antibody-drug conjugates.